Cisplatin and progesterone separate and combined action on rat brain nuclear phospholipids content

Prostaglandins Other Lipid Mediat. 2023 Oct:168:106750. doi: 10.1016/j.prostaglandins.2023.106750. Epub 2023 May 27.

Abstract

The antitumor agent cisplatin and steroid hormone progesterone separate and combined action on content of total phospholipids and their individual classes in nuclei from rat brain cells were investigated. Cisplatin and progesterone exhibit their own characteristic properties, when used separately. Cisplatin reduces, and progesterone, on the contrary, increases the content of total phospholipids. When used together, the effects of these drugs are summed up. Cisplatin reduces the content of all 7 individual phospholipids found in rat brain nuclear preparations. Progesterone, on the other hand, increases the content of 5 classes of phospholipids. The combined use of cisplatin and progesterone restores 5 classes of nuclear phospholipids to the baseline level, and increases the quantity of 2 classes. The obtained results are discussed in terms of antagonistic effects of studied drugs, which can help in reducing undesirable side effects of cisplatin in case of combined use of antitumor drug and steroid.

Keywords: Cisplatin; Nuclei from rat brain cells; Phospholipids; Progesterone.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Cisplatin* / pharmacology
  • Phospholipids
  • Progesterone / pharmacology
  • Rats
  • Steroids

Substances

  • Cisplatin
  • Progesterone
  • Phospholipids
  • Antineoplastic Agents
  • Steroids